Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review

IF 6.1 2区医学 Q1 CLINICAL NEUROLOGY

European Neuropsychopharmacology Pub Date : 2024-11-13 DOI:10.1016/j.euroneuro.2024.10.006

Guido Cammà , Monika P. Verdouw , Pim B. van der Meer , Lucianne Groenink , Albert Batalla

{"title":"Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review","authors":"Guido Cammà , Monika P. Verdouw , Pim B. van der Meer , Lucianne Groenink , Albert Batalla","doi":"10.1016/j.euroneuro.2024.10.006","DOIUrl":null,"url":null,"abstract":"<div><div>Interest in cannabinoids’ therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids’ therapeutic potential in psychiatric disorders.</div><div>22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8‐THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9‐THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 9-24"},"PeriodicalIF":6.1000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0924977X24007508","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Interest in cannabinoids’ therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids’ therapeutic potential in psychiatric disorders.

22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8‐THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9‐THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.

查看原文本刊更多论文

轻微大麻素对精神疾病的治疗潜力：系统综述。

有证据表明，内源性大麻素系统参与了焦虑、抑郁和成瘾等精神疾病的治疗，因此人们对大麻素在精神健康方面的治疗潜力越来越感兴趣。虽然对主要大麻素大麻二酚（CBD）和Δ9-四氢大麻酚（Δ9-THC）的研究更为广泛，但从大麻植物中发现的次要大麻素约有 120 种。虽然其中一些大麻素显示出良好的药理学特征，但有关其在精神疾病方面应用的研究却很零散。本系统性综述首次评估了探索次生大麻素对精神疾病治疗潜力的临床前和临床研究。其中包括 22 项临床前研究和 1 项临床研究，这些研究调查了各种微量大麻素在药物使用障碍、焦虑障碍、抑郁障碍、创伤和压力相关障碍、精神障碍、神经发育障碍和饮食失调中的应用。尽管有几篇文章的研究结果不尽相同，而且存在中度到高度的偏倚风险，但某些化合物显示出了进一步研究的前景。Δ8-四氢大麻双甙 (Δ8-THCV)具有治疗尼古丁成瘾的潜力；Δ9-四氢大麻双甙 (Δ9-THCV)具有治疗精神病样症状的潜力；大麻二酚甲酯 (CBDA-ME) 可减轻焦虑和抑郁样症状，大麻双甙 (CBDV) 可减轻自闭症谱系障碍样症状。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Neuropsychopharmacology 医学-精神病学

CiteScore

10.30

自引率

5.40%

发文量

730

审稿时长

41 days

期刊介绍： European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.